Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Walid Saliba Added: 3 months ago
AF Symposium 25 - Left atrial appendage (LAA) closure using the WATCHMAN FLX device (Boston Scientific) showed lower risk of bleeding and non-inferiority in efficacy endpoints to oral anticoagulation in patients who have received or are planning to receive AF ablation.Dr Walid Saliba (Cleveland Clinic, OH, US) joins us onsite at AF Symposium 25 to discuss the findings from the concomitant and… View more
Author(s): Naima Maqsood , Christian Ruff Added: 1 year ago
AHA 23 - Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews Dr Christian Ruff (Brigham and Women's Hospital, US) on the late-breaking findings from the AZALEA-TIMI 71 randomized trial (Anthos Theraputics, Inc).AZALEA-TIMI 71 aimed to evaluate the bleeding profile of abelacimab as compared to rivaroxaban in patients with atrial fibrillation who are at moderate to… View more
Author(s): Luigi Di Biase Added: 3 months ago
Stay up to date with our video collection covering late-breaking data from AF Symposium 2025 in Boston. Don't miss our short, accessibleExpert Interviews and Highlights of the most pertinent trials. View more
Author(s): Mandeep Mehra , Christian Inchaustegui Added: 1 year ago
AHA 2023 - Investigator, Dr Mandeep Mehra (Brigham and Women's Hospital, US) is interviewed by Dr Christian Inchaustegui (Oregon Health & Science University, US), CardioNerds Ambassador, on the findings of the ARIES HM3 trial (NCT04069156).ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES… View more
Author(s): Naima Maqsood , Jeff Healey Added: 1 year ago
AHA 2023 — Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews investigator, Dr Jeff Healey (McMaster University, CA) to outline the findings from a phase 4 trial of apixaban to reduce thromboembolism in patients with subclinical atrial fibrillation (AF).ARTESiA (NCT01938248) aims to determine if apixaban in combination with aspirin can reduce the instance of… View more
Author(s): Samir R Kapadia Added: 1 year ago
TCT 23 - We are joined by Dr Samir Kapadia (Cleveland Clinic, Cleveland, OH) to discuss the findings of the WATCH-TAVR Trial (NCT03173534). WATCH-TAVR aimed to evaluate the safety and effectiveness of left atrial appendage occlusion with the WATCHMAN device to prevent stroke and bleeding in patients with atrial fibrillation (AF) who are undergoing transcatheter aortic valve replacement (TAVR)… View more
Author(s): Paulus Kirchhof Added: 1 year ago
ESC 2023 — Prof Paulus Kirchhof (University Heart & Vascular Center Hamburg, DE) discusses the findings of the NOAH-AFNET 6 trial (NCT02618577). NOAH-AFNET 6 (Atrial Fibrillation Network, Daiichi Sankyo Europe) was an investigator-initiated, prospective, randomised trial aiming to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy in stroke prevention,… View more
Author(s): Linda Joosten Added: 1 year ago
ESC 2023 — Dr Linda Joosten (Julius Center for Health Sciences and Primary Care, NL) joins us to discuss the findings of the FRAIL-AF trial. FRAIL-AF is a multicentre, open-label randomised controlled clinical trial which studied frail elderly patients who receive vitamin K antagonist (VKA) treatment for atrial fibrillation (AF). Current clinical guidelines recommend non-vitamin K antagonists … View more
Job title: MD, Assistant Professor of Medicine
Author(s): Renato D Lopes Added: 8 months ago
ESC Congress 24 — AF screening with a wearable ECG device increases diagnosis by over 50% but did not significantly reduce hospitalisation rates for stroke.We are joined onsite at ESC Congress 2024 by Dr Renato Lopes (Duke University Medical Center, NC) to discuss the findings from the GUARD-AF Trial (NCT04126486, Bristol-Myers Squibb), which was designed to determine if screening for undiagnosed… View more